Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study

Влияние аторвастатина на регуляцию метаболизма железа у пациентов с хронической болезнью почек: рандомизированное двойное слепое перекрёстное исследование
Michal P. Nowicki, Anna Masajtis‐Zagajewska
2018-10-15

atorvastatinchronic kidney diseasehepcidiniron metabolismrandomized crossover study
INTRODUCTION: To determine the effect of 6-month administration of atorvastatin on hepcidin and hemojuvelin levels, inflammatory parameters and iron metabolism in patients with chronic kidney disease (CKD) stages 3 and 4. METHODS: Thirty six statin- and erythropoiesis-stimulating agent-naive patients with CKD stages 3 and 4 and LDL cholesterol ≥100 mg/dl received atorvastatin or placebo for two 6-month periods in a double blind, randomized crossover study. Hepcidin, hemojuvelin, hsCRP, IL-6, hemoglobin, red blood cell distribution width, iron, total iron binding capacity (TIBC), and unsaturated iron binding capacity (UIBC) were measured before and after each treatment period. RESULTS: Hepcidin decreased (from 102 [307] to 63 [170] pg/ml (p > .001)) in the course of statin therapy but remained unchanged after placebo administration (173 [256] to 153 [204] pg/ml, respectively). Hemojuvelin did not change after either part of the study. Both IL-6 and hsCRP decreased following statin therapy (from 8.7 [12.0] to 8.1 [13.9] pg/ml; p = .04 and from 4.7 [4.0] to 4.0 [3.6] mg/l; p = .4, respectively), but did not change after placebo administration. Blood hemoglobin increased slightly but significantly after 6-month statin therapy (from 11.6 ± 1.6 to 11.9 ± 1.5 g/dl, p = .002), and was unchanged after placebo treatment. TIBC and UIBC increased significantly after 6-month statin therapy, and serum iron also tended to increase. The change of eGFR during the study did not differ between the two treatment periods. CONCLUSIONS: Statin may have a small but potentially beneficial effect on serum hepcidin, which may lead to improvement of anemia control in CKD patients.
1
Atorvastatin lowered IL-6 and hsCRP, indicating reduced inflammatory activity; these parameters were unchanged during placebo treatment.
2
Atorvastatin significantly increased total and unsaturated iron-binding capacities, with serum iron showing a tendency to increase.
3
Hemoglobin increased modestly but significantly after atorvastatin, while remaining unchanged with placebo.
4
Hemojuvelin and the change in eGFR were unaffected by atorvastatin, suggesting the hepcidin effect was not explained by altered kidney-function progression.
5
In statin- and erythropoiesis-stimulating agent-naive CKD stage 3–4 patients, six months of atorvastatin reduced serum hepcidin, unlike placebo.
6
The findings suggest atorvastatin may provide a small, potentially beneficial improvement in anemia control through effects on hepcidin and iron metabolism.

Patients with stage 3–4 chronic kidney disease receiving 6-month atorvastatin therapy

The effects of atorvastatin on hepcidin and hemojuvelin levels, inflammation, iron metabolism, and anemia-related parameters

Publication Details
Publication Date
2018-10-15
Journal
Publisher
ISSN
Cited by
22
Access Type
Author Information
Authors
Michal P. Nowicki
Anna Masajtis‐Zagajewska
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%